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Heat-Not-Burn Tobacco Cigarettes:
Smoke byAnyOther Name
The tobacco industry’s most recent response to the docu-
mented harms of cigarette smoking was to launch new heat-
not-burn (HNB) tobacco cigarettes.1 Philip Morris Interna-
tional (PMI) created IQOS (I-Quit-Ordinary-Smoking):
disposable tobacco sticks
soaked in propylene glycol,
whichare inserted inaholder
in the HNB cigarette. The to-
bacco is heatedwith an electric blade at 350°C. The cigarettes
aremarketedbyPMIas a “revolutionary technology thatheats
tobacco without burning it, giving you the true taste of to-
bacco, with no smoke, no ash and less smell.”2 Inmany coun-
tries, laws that protect people frompassive smoke only apply
to smoked tobaccoproducts.PhilipMorris International claims
that IQOSreleasesnosmokebecause the tobaccodoesnotcom-
bust and the tobacco leaves are only heatednot burned.How-
ever, there can be smoke without fire. The harmful compo-
nents of tobacco cigarette smoke are products of incomplete
combustion (pyrolysis) and the degradation of tobacco ciga-
rettes throughheat (thermogenicdegradation).Completecom-
bustion occurs at a high temperature (>1300°C), higher than
the heat generated by smoking a tobacco cigarette (<800°C).
Typicalmarkers of pyrolysis and thermogenic degradation of
tobacco cigarettes are acetaldehyde, an irritant carcinogenic
volatile organic compound, benzo[a]pyrene, a carcinogenic
polycyclic aromatic hydrocarbon, and carbonmonoxide.
Pilotprograms for IQOSbegan in2014 in Japanand in2015
in Switzerland and Italy. An internet survey in Japan pub-
lished in2015suggestedthatyounger individuals (15 to39years
of age) weremore likely to use IQOS, as were former smokers
and current smokers.3 Since 2016, a total of 19 countries have
allowed the sale of IQOS cigarettes. In June 2016, data from
PMIrevealed that IQOShadcaptured2.2%of thecigarettemar-
ket in Japan. IQOS is not yet sold in the United States, but in
December 2016, PMI submitted amodified risk tobacco prod-
uct application to theUSFoodandDrugAdministration. If suc-
cessful, PMIwill be less restricted in itsmarketing for the IQOS
than for conventional tobacco cigarettes. Smokers and non-
smokersneedaccurate informationabout toxic compounds re-
leased in IQOS smoke. This information should come from
sources independent of the tobacco industry, but the only
analyses we found were from PMI and PMI competitors.1
Methods |Wecomparedthecontentsof IQOS(IQOSHolder, IQOS
Pocket Charger, Marlboro HeatSticks [regular], and Heets,
Philipp Morris SA) smoke with the contents of conventional
cigarettes (Lucky Strike Blue Lights). We used a smoking de-
vice designed and tested in our facility to capture the main-
streamaerosol anddeveloped tomeet standards for common
cigarettes ande-cigarettes.4We followed the InternationalOr-
ganization for Standardization standards for puff volume (35
mL) at 2puffsperminute, basedonobservationof IQOSsmok-
ers,who tookameanof 14puffsduring5 to6minutes.Weana-
lyzed volatile organic compounds and nicotine by gas chro-
matography coupled to a flame ionization detector and
polycyclic aromatichydrocarbonsusinghigh-performance liq-
uidchromatographycoupled toa fluorescencedetector, aspre-
viouslydescribed.4We trappedpolycyclic aromatic hydrocar-
bons from IQOS cigarette smoke in a glass filter (Whatman 37
mmØGF/B)mounted in linewith anXAD2cartridge. For each
sampling, 10 IQOScigaretteswere smoked.Eachsamplingsup-
port was desorbed in 10mL of acetonitrile and sonicated for 1
hour. The eluate was evaporated in a vacuum concentrator
(Speed Vac SC-200, ThermoFisher Scientific) set with 30mil-
libars and 27g until the residue was almost dry to prevent
evaporation of the most volatile polycyclic aromatic hydro-
carbons. The residue was filtered with polytetrafluoroethyl-
ene membrane (Acrodisc CR 13 mm, 0.45 μm, Pall Life Sci-
ences) before it was analyzedwith a high-performance liquid
chromatography device (Ultimate 3000, ThermoFisher Sci-
entific) equipped with a fluorescence detector (FLD-
3000RS), UVdetector (VWD-3000), and a separation column
Nucleodur EC 150 × 3 mm C18 3 μm (Macherey-Nagel) under
isocratic conditions (1.2mL · min−1).We injected 2μL into the
high-performance liquid chromatography chain; methanol/
water (70/30)withacetonitrilewas theeluent solvent at an ini-
tial ratio of 100% to 0% (4 minutes) and a linear gradient up
to 100%acetonitrile (12minutes).We did not analyze polycy-
clic aromatic hydrocarbons generated by conventional ciga-
rettes andpresent themean values in the 35 best-selling ciga-
rettes brands in theUnited States, as reported byVu et al.5We
monitored the temperature near the heater blade inside the
IQOSholderandthecoreof theconventional cigaretteata sam-
pling rate of 3 Hz with a type k thermocouple.
Results | Volatile organic compounds, polycyclic aromatic
hydrocarbons, and carbon monoxide were present in IQOS
smoke (Table). The temperature of the IQOS was lower
(330°C) than the conventional cigarette (684°C).5 The IQOS
smoke had 84% of the nicotine found in conventional ciga-
rette smoke.
Discussion |ThesmokereleasedbyIQOScontainselements from
pyrolysisandthermogenicdegradationthatare thesameharm-
ful constituents of conventional tobacco cigarette smoke. In-
ternational experts were invited by PMI to describe the IQOS
aerosol; one expert claims that “less than 2% by weight of
the aerosol components may derive from the pyrolysis of the
tobacco substrate which would not be sufficient to charac-
terize the aerosol as ‘smoke.’”6(p 2) In contrast, our analyses
reveal that advertising slogans such as “heat-not-burn” are
Editor's Note page 1052
Letters
1050 JAMA Internal Medicine July 2017 Volume 177, Number 7 (Reprinted) jamainternalmedicine.com
© 2017 American Medical Association. All rights reserved.
Downloaded From:  by a University of Bern User  on 03/15/2018
no substitute for science. Dancing around the definition of
smoke to avoid indoor-smoking bans is unethical. Principle 1
for implementing article 8 of the World Health Organization
convention on tobacco control highlights that we should
reject ideas that there is a threshold value for toxic effects
from second-hand smoke. Independent studies should fur-
ther evaluate the health effects of the IQOS. In the mean-
time, heated tobacco products such as IQOS should fall
under the same indoor-smoking bans as for conventional
tobacco cigarettes.
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Table. Concentrations of 8 Volatile Organic Compounds, 16 Polycyclic Aromatic Hydrocarbons, 3 Inorganic Compounds, and Nicotine inMainstream
Aerosol and Temperature of the HNB IQOS Cigarette and Conventional Cigarettes
Analyzed Compound
HNB Cigarette Conventional Cigarette Proportion of theChemical in HNB
and Conventional
Cigarettes, %
Amount,
Mean (SD)
No. of Replications
for Each Assay
Amount,
Mean (SD)
No. of Replications
for Each Assay
Volatile organic compounds, μg per cigarettea
Acetaldehyde 133 (35) 5 610b 1 22
Acetone 12.0 (12.9) 5 95.5 (13.5) 2 13
Acroleine 0.9 (0.6) 2 1.1 1 82
Benzaldehyde 1.2 (1.4) 5 2.4 (2.6) 2 50
Crotonaldehyde 0.7 (0.9) 5 17.4 1 4
Formaldehyde 3.2 (2.7) 5 4.3 (0.4) 2 74
Isovaleraldehyde 3.5 (3.1) 5 8.5 (10.8) 2 41
Propionaldehyde 7.8 (4.3) 5 29.6 (36.6) 2 26
Polycyclic aromatic hydrocarbons, ng per cigarettec
Naphthalene 1.6 (0.5) 4 1105 (269) 7 0.1
Acenaphthylene 1.9 (0.6) 4 235 (39) 7 0.8
Acenaphthene 145 (54) 4 49 (9) 7 295
Fluorene 1.5 (0.6) 4 371 (56) 7 0.4
Anthracene 0.3 (0.1) 4 130 (18) 7 0.2
Phenanthrene 2.0 (0.2) 4 292 (44) 7 0.7
Fluoranthene 7.3 (1.1) 4 123 (18) 7 6
Pyrene 6.4 (1.1) 4 89 (15) 7 7
Benz[a]anthracene 1.8 (0.4) 4 33 (4.2) 7 6
Chrysene 1.5 (0.3) 4 48 (6.2) 7 3
Benzo[b]fluoranthene 0.5 (0.2) 4 24 (2.9) 7 2
Benzo[k]fluoranthene 0.4 (0.2) 4 4.3 (2.8) 7 9
Benzo[a]pyrene 0.8 (0.1) 4 20 (2.9) 7 4
Indeno[1,2,3-cd]pyrene ND 4 NA NA NA
Benzo[ghi]perylene ND 4 NA NA NA
Dibenzo[a,h]anthracene ND 4 NA NA NA
Inorganics, ppm in the mainstream smoked
Carbon dioxide 3057 (532) 5 >9000 3 NA
Carbon monoxide 328 (76) 5 >2000 3 NA
Nitric oxide 5.5 (1.5) 5 89.4 (71.6) 3 6
Other measures
Nicotine, μg per cigarettea 301 (213) 4 361 1 84
Temperature, °C 330 (10) 2 684 (197) 1 NA
Puff total count 12.6 (2.4) 32 13.3 (3.1) 6 NA
Abbreviations: HNB, heat-not-burn; NA, not analyzed; ND, not detected.
a We applied themethods described previously in Varlet et al4 to analyze
volatile organic compounds and nicotine.
bBecause there was only 1 replication, no SD can be computed.
c We present values reported from Vu et al5 for the ISO smoking regimen and
for a mean of the 35 top-selling US cigarette brands.
d Carbon dioxide wasmeasured with a Testo 535 (Testo), and carbonmonoxide
and nitric oxide weremeasured with a Pac 7000 that detected carbon
monoxide (Draeger). The apparatus measured the smoke when it was released
from the syringe pump.
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Editor's Note
No Smoke—Just Cancer-Causing Chemicals
Heat-not-burn tobacco products are for sale around the
world. Although they are not yet on the market in the United
States, Phillip Morris International has applied to the US Food
and Drug Administration (FDA) to sell these products. These
products threaten the progress that has been made on
decreasing the harms of second-hand smoke because exist-
ing bans may not apply to these heat-not-burn products.
However, as convincingly reported by Auer and colleagues,1
although these products may or may not produce smoke,
they release cancer-causing chemicals. As shown in their
table, heat-not-burn cigarettes release similar levels of many
volatile organic compounds and nicotine as conventional
cigarettes and higher levels of the polycyclic aromatic hydro-
carbon acenaphthene than conventional cigarettes. They are
bad for health because they release cancer-causing chemi-
cals, and I hope the FDA will not approve them for that
important reason. If the FDA does approve the sale of these
products, existing smoking bans should be amended to
include these products.
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COMMENT&RESPONSE
Neuroleptics for Delirium:More Research Is Needed
To the Editor We read with interest the Original Investigation
in a recent issue of JAMA Internal Medicine by Agar et al1 on
the management of delirium in the palliative care setting.
Delirium is one of the most common and disturbing syn-
dromes at the end of life,2 and there are few well-designed
studies to inform practice.3 Because data from geriatrics and
other populations cannot be extrapolated to the palliative
care setting, this important study1 provides unique insights
into the role of haloperidol and risperidone compared with
placebo; however, several issues regarding the study design
complicate its interpretation.
We wonder if the composite subscore of the Nursing De-
liriumScreeningScale (NuDesc) is anappropriateprimaryout-
come.AlthoughNuDeschas beenvalidated, this subscorehas
not been studied before, and the minimal clinical important
difference has not been defined. While haloperidol and ris-
peridone arms were associated with statistically significant
worseNuDesc subscores, themagnitudeof changemaynotbe
clinically meaningful based on the investigator-defined cut-
off (<1 point).
If haloperidol and risperidone were indeed ineffective,
could the low medication doses explain it? In our acute pal-
liativecareunit,dailyhaloperidoldosesofmore than8mgwere
oftenneeded forpatientswhowereagitated.4,5Weare also cu-
rious that despite the low dose and short duration of neuro-
leptic use,Agar et al1 reported shortened survivalwith risperi-
done. Given the large number of secondary outcomes, these
findings should be considered as hypothesis-generating, and
further studies are needed.
These are confusing times. Clinicians caring for patients
withagitateddeliriumhave tograpplewith thedilemmaofun-
certainbenefits andpotential riskswithneuroleptics for adis-
tressing condition for which few other proven interventions
areavailable.While identificationof reversiblecausesandnon-
pharmacological measures seem intuitive, these interven-
tions need to be standardized and tested formally in the pal-
liative care setting in which delirium is often severe,
progressive, and irreversible. For the large portion of patients
whodonot respond to thesemeasures, neurolepticsmay still
have a role for refractory agitation. This study also reopens
the debate on whether benzodiazepines alone should be con-
sidered for delirium. Given this is a single study enrolling pre-
dominantly patients with mild delirium (median Memorial
Delirium Assessment Scale score, 13-15), it is premature to
close the chapter on neuroleptics in palliative care as sug-
gested by the authors and the accompanying editorial.1
Instead, this study highlights the tremendous opportunities
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